Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
DTx Pharma logo — Pioneering technology to make RNA-based therapeutics the pre...

DTx Pharma

Pioneering technology to make RNA-based therapeutics the preferred choice for personalized treatments across various therapeutic areas.

Founded 2017 11-50 employees Series B Total: $113.60M Biotechnology, Health and Wellness +1

General Information

Company Name DTx Pharma
Founded Year 2017
Employees 11-50
Industries Biotechnology, Health and Wellness, Pharmaceutical
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with DTx Pharma. To contact DTx Pharma, visit dtxpharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does DTx Pharma compare?

A PDF of DTx Pharma and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting DTx Pharma soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About DTx Pharma

DTx Pharma is a biotechnology and pharmaceutical startup that was founded in 2017. The company has a pioneering approach aimed at making RNA-based therapeutics the preferred choice for personalized treatments across various therapeutic areas. DTx Pharma's unique technology addresses challenges that have previously hindered the widespread adoption of RNA medicines, including poor pharmacokinetics and inadequate cellular uptake. In a recent funding round in March 2021, DTx Pharma secured a significant $100.00M Series B investment. The funding was provided by a notable group of investors including RA Capital Management, Viva BioInnovator, ExSight Ventures, Access Biotechnology, Eli Lilly, Janus Handerson, Logos Capital, Tachyon Ventures, Friedman BioVentures, and Surveyor Capital. With its innovative technology and strong backing from prominent investors, DTx Pharma is well-positioned to play a significant role in advancing RNA-based therapeutics and personalized medicine.

Taxonomy: RNA-based therapeutics, personalized treatment, pharmacokinetics, cellular uptake, pharmaceuticals

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Series B $100.00M 10
RA Capital Management Viva BioInnovator ExSight Ventures
RA Capital Management, Viva BioInnovator +8
01 Mar 2021
Grant Undisclosed -
21 Sep 2020
Series A $10.60M -
06 Jan 2020
Series A $3.00M -
14 May 2019
Convertible Note Undisclosed -
01 Jun 2018

DTx Pharma Alternatives & Competitors

View All Alternatives
DTx Pharma vs
MiNA Therapeutics
MiNA Therapeutics United Kingdom

Activating RNA, mastering disease

Corporate Round
34 employees
Biotechnology, Life Sciences
DTx Pharma vs
Rona Therapeutics
Rona Therapeutics China

Empower Great People To Do Great Things

Series A
10 employees
Biotechnology, Health Care
DTx Pharma vs
Skyhawk Therapeutics
Skyhawk Therapeutics United States

We Use Small Molecules To Modify RNA Splicing

Venture round
81 employees
Biotechnology, Health and Wellness
View all alternatives

FAQ About DTx Pharma

Pioneering technology to make RNA-based therapeutics the preferred choice for personalized treatments across various therapeutic areas.
DTx Pharma was founded in 2017.
DTx Pharma operates in Biotechnology, Health and Wellness and Pharmaceutical. Its work centres on RNA-based therapeutics, personalized treatment, pharmacokinetics and cellular uptake.
DTx Pharma has approximately 11-50 employees.
DTx Pharma has completed 5 funding rounds, raising a total of $113.60M. The latest funding stage is Series B.
Top alternatives and competitors to DTx Pharma include MiNA Therapeutics, Rona Therapeutics, Skyhawk Therapeutics, Cardior Pharmaceuticals, Serina Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
DTx Pharma and MiNA Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for DTx Pharma, https://bouncewatch.com/company/dtx-pharma, updated 10 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes